Benzimidazole analogues active against adult Schistosoma mansoni: SAR analyses, In vivo efficacy in mice, and preliminary mechanistic studies as potential inhibitors of hemozoin formation,European Journal of Medicinal Chemistry

当前位置： X-MOL 学术 › Eur. J. Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Benzimidazole analogues active against adult Schistosoma mansoni: SAR analyses, In vivo efficacy in mice, and preliminary mechanistic studies as potential inhibitors of hemozoin formation
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2024-12-19 , DOI: 10.1016/j.ejmech.2024.117186
Godwin A. Dziwornu, Henrietta Dede Attram, Cécile Haberli, Keabetswe Masike, Mathew Njoroge, Jennifer Keiser

For over three decades, praziquantel (PZQ) has been the mainstay chemotherapy for prevention and treatment of schistosomiasis. The excessive use of PZQ, coupled with the lack of advanced drug candidates in the current anti-schistosomiasis drug development pipeline, emphasizes the genuine need for new drugs. In the current work, we investigated the antischistosomal potential of a new series of compounds derived from the privileged benzimidazole scaffold, which exhibited low micromolar IC₅₀ potency in the range of 1.0 – 2.7 μM against S. mansoni adult worms, in vitro. However, representative compounds showed low in vivo activity. One compound (15) reduced worm burden by 51.9% but not significant. Furthermore, by invoking inhibition of hemozoin formation, an immutable drug target in Schistosoma adult worms, as a likely contributing mode of action, we observed that the most potent analogues were equally potent inhibitors of β-hematin (synthetic hemozoin) formation in a cell-free assay.

更新日期：2024-12-20

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南